Articles From: Baxter Appoints Todd Young as Treasurer and Corporate Officer to Baxter to Present at the 25th Annual Piper Jaffray Healthcare Conference


2013/9/9
Baxter International Inc. (NYSE:BAX) announced today that its Board of Directors has elected Todd S.
Sign-up for Baxter Appoints Todd Young as Treasurer and Corporate Officer investment picks
Baxter International Inc. (NYSE: BAX) today announced that the company has successfully completed the acquisition of Gambro AB, a privately held global medical technology company and leader in dialysis products based in Lund, Sweden.
Sign-up for Baxter Completes Acquisition of Gambro AB and Enhances Global Leadership in Renal Therapies investment picks
Baxter International Inc. (NYSE:BAX) today announced completion of CE marking in Europe for the VIVIA hemodialysis (HD) system, designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, known as High Dose HD therapy 1 .
Sign-up for Baxter Completes CE Mark Approval for VIVIA Hemodialysis System in Europe investment picks
2013/11/13
Baxter International Inc. (NYSE:BAX) today announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII (rFVIII) treatment for hemophilia A.
Sign-up for Baxter Completes Enrollment in Phase III Clinical Trial of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A investment picks
2013/11/12
The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.49 per Baxter common share.
Sign-up for Baxter Declares Quarterly Dividend investment picks
2014/2/18
The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.49 per Baxter common share.
Sign-up for Baxter Declares Quarterly Dividend investment picks
Baxter International Inc. (NYSE:BAX) today announced that it has submitted an application to the United States Food and Drug Administration (FDA) for a pediatric indication for RIXUBIS [Coagulation Factor IX (Recombinant)] to treat hemophilia B.
Sign-up for Baxter Files for Pediatric Indication of RIXUBIS [Coagulation Factor IX (Recombinant)] Treatment for Hemophilia B in the United States investment picks
2014/4/3
Baxter International Inc. (NYSE:BAX) will host a quarterly conference call to discuss its first quarter 2014 financial results on Thursday, April 17, 2014, at 7:30 a.m. Central Time.
Sign-up for Baxter International First Quarter 2014 Financial Results Conference Call investment picks
2014/1/6
Baxter International (NYSE:BAX), will host a quarterly conference call to discuss its fourth quarter 2013 financial results on Thursday, January 23, 2014, at 7:30 a.m. Central Time.
Sign-up for Baxter International Fourth Quarter 2013 Financial Results Conference Call investment picks
2014/3/26
Baxter International Inc. (BAX) is considering a sale of its vaccines business, Reuters reported, citing people familiar with the matter.
Sign-up for Baxter International Mulls Sale of Vaccines Business -Reuters investment picks
Baxter International (NYSE:BAX), will host a quarterly conference call to discuss its third quarter 2013 financial results on Thursday, October 17, 2013, at 7:30 a.m. Central Time.
Sign-up for Baxter International Third Quarter 2013 Financial Results Conference Call investment picks
Baxter International Inc. (NYSE:BAX) today announced the launch of HEMOPATCH Sealing Hemostat, a novel collagen-based hemostatic device, following CE mark approval in Europe.
Sign-up for Baxter Launches HEMOPATCH, an Innovative Sealing Hemostat, in European Union investment picks
2013/10/17
Baxter International Inc. (NYSE:BAX) today posted solid financial results for the third quarter which met expectations as the company further augmented its portfolio with the acquisition of Gambro AB, and continued to advance its new product pipeline by launching new products, achieving multiple regulatory milestones, and establishing new collaborations.
Sign-up for Baxter Meets Expectations with Solid Financial Results for the Third Quarter 2013 investment picks
2014/3/27
By Tess Stynes Baxter International Inc. said it plans to create separate, independent health-care companies, one focused on developing and marketing biopharmaceuticals and the other on medical products.
Sign-up for Baxter plans to split into two companies investment picks
2014/2/27
Baxter International Inc. (NYSE:BAX) today presented clinical data on Baxter’s leading recombinant factor VIII treatment, including interim data from the first year of observation from the AHEAD (ADVATE HaEmophilia A Database) study, a four-year outcomes registry of hemophilia A patients treated with ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method]. These data were presented during the European Association for Haemophilia and Allied Disorders (EAHAD) meeting in Brussels, Belgium.
Sign-up for Baxter Presents Data at EAHAD from Long-Term Outcomes Registry Reinforcing Prophylaxis Treatment Experience with ADVATE investment picks
By Joseph Walker Baxter International Inc.'s (BAX) third-quarter earnings fell nearly 7%, hurt by recent acquisition costs and higher legal and tax expense.
Sign-up for Baxter Profit Falls on Acquisition Costs -- Update investment picks
Baxter International Inc. (NYSE: BAX) continued to advance sustainability within the organization by adding Business Resource Groups (BRGs) that support an inclusive and diverse work environment and encouraging employee health and wellness through its recent BeWell@Baxter Exercise Challenge.
Sign-up for Baxter Promotes Wellness, Inclusion and Diversity among Its Employees, is Recognized for Ongoing Sustainability Efforts investment picks
2013/12/19
Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) granted approval of Baxter’s FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.
Sign-up for Baxter Receives FDA Approval of FEIBA [Anti-Inhibitor Coagulant Complex] for Prophylactic Treatment of Hemophilia A&B Patients with Inhibitors investment picks
2014/1/23
Baxter International Inc. (NYSE:BAX) today announced financial results for the fourth quarter of 2013, and provided its financial outlook for the first quarter and full-year 2014.
Sign-up for Baxter Reports Fourth Quarter 2013 Financial Results in Line with Expectations investment picks
2013/12/2
Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced today that Baxter has completed submission of an amended biologics license application (BLA) to the United States Food and Drug Administration (FDA) to re-initiate the review process for approval of HyQvia [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] facilitated subcutaneous infusion for the treatment of adult patients with primary immunodeficiency (PI). HyQvia is a combination of human immune globulin (IG) and recombinant human hyaluronidase.
Sign-up for Baxter Submits Amended BLA to U.S. FDA for HyQvia for Primary Immunodeficiency investment picks
2013/10/31
Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for approval of RIXUBIS, recombinant factor IX (nonacog gamma) for the treatment and prophylaxis of bleeding in patients of all ages with hemophilia B.
Sign-up for Baxter Submits Application for European Approval of RIXUBIS, Recombinant Factor IX (nonacog gamma) for Hemophilia B investment picks
2013/12/10
Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of OBI-1, a recombinant antihemophilic porcine sequence factor VIII, in patients with acquired hemophilia A.
Sign-up for Baxter Submits Application for FDA Approval of OBI-1 for Patients with Acquired Hemophilia A investment picks
2014/4/2
Baxter International Inc. (NYSE:BAX) and Chatham Therapeutics, LLC, today announced that Baxter has agreed to acquire all of Chatham’s outstanding membership interests.
Sign-up for Baxter to Acquire Chatham Therapeutics investment picks
Baxter International Inc. (NYSE: BAX) announced that it will present at the 32 nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 1:00 p.m. (CT). The live webcast of Baxter’s presentation along with the slides can be accessed from the Baxter corporate website at www.baxter.com and will be available for replay through February 9, 2013 Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Sign-up for Baxter to Present at 32nd Annual J.P. Morgan Healthcare Conference investment picks
2014/2/27
Baxter International Inc. (NYSE: BAX) announced today that it will present at Barclay’s Global Healthcare Conference on Tuesday, March 11 th at 7:00 a.m. (CT). The live webcast of Baxter’s presentation can be accessed from the Baxter corporate website at www.baxter.com and will be available for replay through April 10, 2014.
Sign-up for Baxter to Present at Barclay’s Global Healthcare Conference investment picks
2014/2/13
Baxter International Inc. (NYSE: BAX) announced today that it will present at the Cowen & Company’s 34 th Annual Health Care Conference on Monday, March 3, 2014 at 2:30 p.m. (CT). The live webcast of Baxter’s presentation can be accessed from the Baxter corporate website at www.baxter.com and will be available for replay through April 2, 2014.
Sign-up for Baxter to Present at Cowen & Company’s 34th Annual Health Care Conference investment picks
Baxter International Inc. (NYSE: BAX) announced today that it will present at the Morgan Stanley Global Healthcare Conference on Monday, September 9, 2013 at 3:25 p.m. (CT). The live webcast of Baxter’s presentation can be accessed from the Baxter corporate website at www.baxter.com and will be available for replay through October 9, 2013.
Sign-up for Baxter to Present at Morgan Stanley Global Healthcare Conference investment picks
Baxter International Inc. (NYSE: BAX) announced today that it will present at the 2013 Credit Suisse Healthcare Conference on Wednesday, November 13, 2013 at 9:30 a.m. (CT). The live webcast of Baxter’s presentation can be accessed from the Baxter corporate website at www.baxter.com and will be available for replay through December 12, 2013.
Sign-up for Baxter to Present at the 2013 Credit Suisse Healthcare Conference investment picks
Baxter International Inc. (NYSE: BAX) announced today that it will present at the 25 th Annual Piper Jaffray Healthcare Conference Tuesday, December 3, 2013 at 12:00 p.m. (CT). The live webcast of Baxter’s presentation can be accessed from the Baxter corporate website at www.baxter.com and will be available for replay through January 2, 2014.
Sign-up for Baxter to Present at the 25th Annual Piper Jaffray Healthcare Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Baxter Appoints Todd Young as Treasurer and Corporate Officer to Baxter to Present at the 25th Annual Piper Jaffray Healthcare Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity